Prostate Cancer Treatment Paradigm to See Huge Changes, States GlobalData in Its New Report Published at MarketPublishers.com
26 Oct 2016 • by Natalie Aster
LONDON – Excluding certain forms of skin cancer, prostate cancer is the prevailing type of cancer identified in men worldwide (15% of all the cancer types), thus placing a huge burden on health care systems. Patients that are diagnosed with localized, early-stage prostate cancer can be healed up, while patients that progress to an advanced form of prostate cancer (castration-resistant prostate cancer, CRPC) have no curative treatment options.
Since 2010, 5 novel drugs have been approved to treat CRPC: Sanofi’s Jevtana, Dendreon’s Provenge, Medivation/Astellas’ Xtandi, Bayer’s Xofigo, and Johnson & Johnson’s Zytiga. Through to 2023, 9 new late-stage pipeline drugs are anticipated to be launched, with 8 of which poised to be aimed at treating CRPC. Owing to this unparalleled level of clinical research, the CRPC treatment paradigm is forecast to see huge changes in the foreseeable future. Additionally, on account of the influx of novel therapies, the prostate cancer market size across the 5EU leading pharma markets is projected to expand threefold.
The 5EU is the dominant prostate cancer market, being second only to the USA. The robust growth is set to originate from the surging incidence rates of prostate cancer with the ageing populations, a hike in sales stemming from the introduction of 8 novel premium priced pipeline drug products in the coming years, and the label extension of Xtandi in the treatment of the non-metastatic CRPC and hormone-sensitive prostate cancer population of patients.
New research report “Prostate Cancer - 5EU Drug Forecast and Market Analysis to 2023” created by GlobalData covers the present-day treatment landscape, various unmet needs, pipeline analysis and a detailed outlook for the prostate cancer marketplace.
The study gives a review of the disease including epidemiology, symptoms, etiology, diagnosis, pathology and treatment regimens and also insights into the competitive scenario. It gives details about the key drugs across 5EU, covering product descriptions, efficacy and safety profiles, and also a granular SWOT analysis. The report includes a comprehensive sales forecast for the leading drugs in the region to 2023. An in-depth examinaiton of the influence of key events in tandem with key drivers and restraints impacting the 5EU prostate cancer sector is available, too.
More new research reports by the publisher can be found at GlobalData page.